February 11, 2021 11:00 AM EST

Dyno sketches tens of thousands of viable next-gen AAV capsids with the help of machine learning — paper

Kyle Blankenship

Since its launch in May 2020, Dyno Therapeutics has touted its platform’s potential to discover viable variations of current-gen AAVs with noticeable limitations in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dyno sketches tens of thousands of viable next-gen AAV capsids with the help of machine learning — paper

Kyle Blankenship

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Dyno sketch­es tens of thou­sands of vi­able next-gen AAV cap­sids with the help of ma­chine learn­ing — pa­per

Kyle Blankenship

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Dyno sketches tens of thousands of viable next-gen AAV capsids with the help of machine learning — paper

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role